The Patent Finder

Methods and Compositions for the Treatment of Cns-Related Conditions

Adamas Pharmaceuticals, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresPatent lifetimeUsedRemainingConfidence
US 8,058,291Methods and Compositions for the Treatment of Cns-Related Conditions
In force
 · Medium confidence
UsedRemaining
Adamas Pharmaceuticals, Inc.In forceMedium confidence
US 7,619,007Method and Composition for Administering an Nmda Receptor Antagonist to a Subject
Term ended
Ended no later than Nov 22, 2025 · Medium confidence
Adamas Pharmaceuticals, Inc.Term endedEnded no later than Nov 22, 2025Medium confidence
US 8,173,708Method and Composition for Administering an Nmda Receptor Antagonist to a Subject
Term ended
Term ended Nov 22, 2025 · Medium confidence
Adamas Pharmaceuticals, Inc.Term endedTerm ended Nov 22, 2025Medium confidence
US 8,283,379Methods and Compositions for the Treatment of Cns-Related Conditions
Term ended
Term ended Nov 22, 2025 · Medium confidence
Adamas Pharmaceuticals, Inc.Term endedTerm ended Nov 22, 2025Medium confidence
US 8,293,794Methods and Compositions for the Treatment of Cns-Related Conditions
Term ended
Term ended Nov 22, 2025 · Medium confidence
Adamas Pharmaceuticals, Inc.Term endedTerm ended Nov 22, 2025Medium confidence
US 8,329,752Composition for Administering an Nmda Receptor Antagonist to a Subject
Term ended
Ended no later than Nov 22, 2025 · Medium confidence
Adamas Pharmaceuticals, Inc.Term endedEnded no later than Nov 22, 2025Medium confidence
US 8,338,485Compositions for the Treatment of Cns-Related Conditions
Term ended
Ended no later than Nov 22, 2025 · Medium confidence
Adamas Pharmaceuticals, Inc.Term endedEnded no later than Nov 22, 2025Medium confidence
US 8,338,486Methods for the Treatment of Cns-Related Conditions
Term ended
Ended no later than Nov 22, 2025 · Medium confidence
Adamas Pharmaceuticals, Inc.Term endedEnded no later than Nov 22, 2025Medium confidence
US 8,362,085Method for Administering an Nmda Receptor Antagonist to a Subject
Term ended
Ended no later than Nov 22, 2025 · Medium confidence
Adamas Pharmaceuticals, Inc.Term endedEnded no later than Nov 22, 2025Medium confidence
US 8,426,472Method and Composition for Administering an NMDA Receptor Antagonist to a Subject
Term ended
Term ended Nov 22, 2025 · Medium confidence
Adamas Pharmaceuticals, Inc.Term endedTerm ended Nov 22, 2025Medium confidence
23 more records in this group · Pro
10 of 33 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 33, including 12 expired.
Upgrade to Pro
1 of these is in force and held by Adamas Pharmaceuticals, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited